ANALYSIS OF CONSUMPTION OF DIURETICS IN SERBIA IN THE PERIOD FROM 2006 TO 2010 YEAR
Author(s)
Tomic Z*;Sabo A;Mikov M;Milijasevic B;Milijasevic D, Vukmirovic S Faculty of Medicine, University of Novi Sad, Serbia, Novi Sad, Serbia and Montenegro
OBJECTIVES: Diuretics are drugs of first choice in the treatment of hypertension. The aim of this study was to analyze the consumption of diuretics in Serbia in the period from 2006 to 2010 year. METHODS: The data about the use of drugs were taken from the Agency for Drugs and Medical Devices of the Serbia. RESULTS: The use of diuretics during the observed period in Serbia is quite small and it ranged from 5 to 6% of the total consumption of all drugs from the C group. Furosemide was the most frequently used diuretic. In the five year period furosemide consumption ranged from 33-55% of the total consumption of all diuretics. The second largest consupmtion during first four years of the study was that of indapamide. Indapamide consumption in the fifth year was at the fourth position. At the third position in drug consumption in the first four years was hydrochlorothiazide. Use of hydrochlorothiazide in 2010 took second place. Spironolactone has occupied the fourth position in the first four years. During the last years of the period spironolactone occupied the third position. Consumption of all other diuretics was small and it was only a few percent of the total consumption of all diuretics. CONCLUSIONS: In Serbia, in the observed period, consumption of diuterics is two to three times lower in comparison with the consumption of diuretics in Norway and Finland. This research was supported by Provincial Secretariat for Science and Technological Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 41012.
Conference/Value in Health Info
2013-09, ISPOR Latin America 2013, Buenos Aires, Argentina
Value in Health, Vol. 16, No. 7 (November 2013)
Code
PCV9
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Cardiovascular Disorders